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Abstract: Neurodegenerative diseases are age-related disorders caused by progressive neuronal 
death in different regions of the nervous system. Neuroinflammation, modulated by glial cells, is a 
crucial event during the neurodegenerative process; consequently, there is an urgency to find new 
therapeutic products with anti-glioinflammatory properties. Five new furanocembranolides (15), 
along with leptolide, were isolated from two different extracts of Leptogorgia sp., and compound 6 
was obtained from chemical transformation of leptolide. Their structures were determined based 
on spectroscopic evidence. These seven furanocembranolides were screened in vitro by measuring 
their ability to modulate interleukin-1β (IL-1β) production by microglial BV2 cells after LPS 
(lipopolysaccharide) stimulation. Leptolide and compounds 3, 4 and 6 exhibited clear anti-
inflammatory effects on microglial cells, while compound 2 presented a pro-inflammatory outcome. 
The in vitro results prompted us to assess anti-glioinflammatory effects of leptolide in vivo in a 
high-fat diet-induced obese mouse model. Interestingly, leptolide treatment ameliorated both 
microgliosis and astrogliosis in this animal model. Taken together, our results reveal a promising 
direct biological effect of furanocembranolides on microglial cells as bioactive anti-inflammatory 
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molecules. Among them, leptolide provides us a feasible therapeutic approach to treat 
neuroinflammation concomitant with metabolic impairment. 
Keywords: Leptogorgia; furanocembranolides; leptolide; microglia; astrocytes; gliosis; anti-
inflammatory compounds; bioactive natural products; drug discovery; high-fat diet 
 
1. Introduction 
It has been estimated that, by the year 2050, 1 in 6 people in the world will be over the age of 65 
[1]. In other words, over the next three decades, the global number of people over the age of 60 is 
predicted to more than double, reaching over 1.5 billion people worldwide in 2050 [1]. Due to the 
increase in life expectancy, age-related diseases are expected to rise in incidence. One of the most 
prominent groups of these diseases are neurodegenerative disorders, characterized by the loss of 
neurons within the brain and/or spinal cord [2]. Consequently, the prevalence of neurodegenerative 
diseases is also expected to rise dramatically in the next few decades, with the resultant additional 
socioeconomic burden. Therefore, drugs to slow down or stop the neurodegenerative process are 
urgently needed [3]. 
Common factors that are potential mediators of the neurodegenerative process include 
increased oxidative stress, impaired energy metabolism, lysosomal dysfunction, protein aggregation, 
inflammation, excitoxicity, necrosis and/or apoptosis [4]. The “neurocentric” approach to treat 
neurodegenerative diseases has dominated the research focus for many years, with great efforts to 
develop drugs to avoid neuronal death. Nevertheless, with the increasing knowledge about glial 
cells, it is becoming evident that controlling inflammation within the brain requires the study of glia. 
Hence, an expansion from an exclusively “neurocentric” to a “gliocentric” focus would improve the 
prospects of improved future therapeutic strategies against neurodegeneration. 
The brain was considered an immunologically privileged organ until a few years ago, but 
nowadays, it is accepted that both microglia and astrocytes are involved in modulating inflammation 
within the central nervous system (CNS). Microglia are the resident immune cells of the CNS and 
play a crucial role in brain homeostasis during aging. In fact, microglial cells are the most important 
players in the communication route between the CNS and the peripheral immune system [5,6]. 
Consequently, microglial cells are highly sensitive to small changes in the brain microenvironment 
in order to switch their functions to maintain brain equilibrium. Similarly to peripheral macrophages, 
microglia have been often classified into either “classically” or “alternatively” activated phenotypes 
[7,8]. However, this categorization is oversimplified given their high degree of diversity and plasticity 
[9]. During recent years, this concept is being replaced by a spectrum of activation patterns of 
microglial cells, for which the extremes are pro- and anti- inflammatory phenotypes [10]. Mounting 
evidence suggests that certain situations such as infection or aging can alter the threshold for 
microglial activation. This has a profound impact on microglial phenotypes, switching towards a pro-
inflammatory state that triggers maladaptive responses that contribute to the onset and progression 
of some CNS diseases [11]. 
While microglia have their own inflammatory phenotype axis, they also modulate pro-
inflammatory and neurotoxic activities in astrocytes in different ways. Classically activated microglia 
promote astrocyte differentiation into a reactive state by secreting pro-inflammatory cytokines such 
as IL-1β and tumor necrosis factor alpha (TNF-α) [12]. Moreover, in the injured brain, astrocytes are 
reported to act as controllers to rapidly restrain microglial activation, thus avoiding exacerbated 
responses to injuries [13]. Such evidence suggests there is a tightly regulated equilibrium between 
glial cells that regulates local immune reactions within the brain. 
Octocorals of the genus Leptogorgia produce furanocembranolides, highly oxygenated 
diterpenes into which a γ-lactone subunit is embedded. Marine furanocembranolides can be divided 
into four different classes: those in which the substituent at the C-4 position is a CH3 (class A), those 
with CHO (class B), those with COOH (class C) and those with COOCH3 (class D) [14,15]. Although 
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the pharmacological potential of this family of diterpenes is largely unexplored, a few examples of 
anti-inflammatory activity have been reported. Among them, sinulacembranolide A and crassarine 
H were found to significantly reduce the levels of the pro-inflammatory protein iNOS (inducible 
nitric oxide synthase) relative to control cells stimulated with LPS (lipopolysaccharide) only [16,17]. 
Increasing evidence based on epidemiological studies and preclinical models suggests that a 
strong link exists between metabolic dysfunction and neurodegeneration. In fact, impaired energy 
metabolism is a hallmark of neurodegenerative disorders [18,19]. Interestingly, diabetes mellitus 
patients are predisposed to suffer from dementia. Some of the known mechanisms leading to this 
complication are changes in the vasculature structure and function, glucose metabolism 
dysregulation, insulin signalling impairment, inflammation, and modifications in processing and 
degradation of amyloid beta and hyperphosphorylated tau [20–22]. Regarding the family of 
furanocembranolides, leptolide has been shown to act as an insulin sensitizer, enhancing insulin 
signalling and sensitivity in the liver and muscle of high-fat diet-induced obese mice [23]. Leptolide 
reduced weight gain in these mice in parallel with decreased circulating pro-inflammatory cytokines 
and leptin. These results led us to hypothesize that furanocembranolides, due to their beneficial 
effects on metabolism and systemic inflammation, could also have beneficial effects on the CNS and 
potentially counteract the complications developed in a preclinical model of high-fat diet-induced 
obesity and insulin resistance. 
These antecedents prompted us to re-examine two extracts of Leptogorgia sp., from which new 
furanocembranolides 1–5 were obtained, together with the previously known leptolide (7) [14]. 
Furthermore, we treated leptolide to obtain compound 6 (Figure 1) to assess a new 
furanocembranolide with different substituents at position C-4. 
We assayed the potential anti-inflammatory effects of seven members of the furanocembranoid 
family in vitro by measuring their capacity to diminish IL-1β mRNA production by microglial BV2 
cells after LPS (lipopolysaccharide) stimulation. Among the compounds that showed anti-
inflammatory effects in vitro, we chose leptolide to appraise its anti-glioinflammatory potential in 
vivo, treating high-fat diet-induced obese mice with leptolide and quantifying gliosis. Taken 
together, our results reveal a promising effect of furanocembranolides as bioactive anti-inflammatory 
molecules, and we propose leptolide as a feasible therapeutic approach to reduce the 
neuroinflammation concomitant with metabolic impairment. 
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Figure 1. Novel furanocembranolides (16) and leptolide (7). 
2. Results 
2.1. Characterization of Novel Furanocembranolides 
Leptogorgodiol A (1), obtained as an oil, showed a peak at m/z [M]+ 376 in the electron impact 
mass spectrometry (EIMS) spectrum corresponding to the molecular formula C20H24O7 (High 
resolution electron impact mass spectrometry(HREIMS)) (m/z 376.1514 [M]+ calcd. for C20H24O7 
376.1522). The diterpenic nature of 1 is confirmed by 13C nuclear magnetic resonance (NMR) and 
heteronuclear single quantum correlation (HSQC) spectra indicative of seven quaternary carbons, six 
methines, five methylenes and two methyls (Table 1). Absorptions for a hydroxyl group at 3478 cm−1 
and carbonyl groups at 1774 and 1672 cm−1 were observed in the infrared (IR) spectrum. 
Significant 1H and 13C NMR signals were an aldehyde group (H-18 9.89 (1H, s) and C-18 184.7), a 
trisubstituted furane ring (H-5 6.69 (1H, s), C-5 106.4, C-3 162.4, C-6 155.2 and C-4 123.2), a ,-epoxy-
-lactone ring (H-11 3.70 (1H, s), C-11 63.0, C-20 172.5, H-10 4.85 (1H, dd, J = 5.0, 11.0 Hz), C-10 74.5 and 
C-12 61.0) and an isopropenyl group (C-15 144.9, H-16a 4.97 (1H, dd, J = 1.6, 1.6 Hz), H-16b 5.10 (1H, s), 
C-16 114.1, H-17 1.77 (3H, s) and C-17 18.8). Information obtained from homonuclear correlation 
spectroscopy (COSY), HSQC and heteronuclear multiple-bond correlation spectroscopy (HMBC) 
experiments unambiguously established the planar structure of compound 1 as a 
furanocembranolide that contains a C-18 oxidized to aldehyde, a vicinal diol at C-7C-8, a C-1C-20 
α,β-epoxy-γ-lactone moiety and an isopropenyl group at C-1. 
Table 1. 1H and 13C NMR spectroscopic data (500 and 125 MHz, CDCl3) of compounds 1 and 2. 
No. 
1 2 
δC, Type δH (J in Hz) δC, Type δH (J in Hz) 
1 40.1, CH 3.24, m 40.2, CH 3.27, dd (11.2, 11.2) 




2.96, dd (2.9, 16.8) 
3.05, dd (11.8, 16.8) 
Mar. Drugs 2020, 18, 378 5 of 22 
 
3 162.4, C - 162.6, C - 
4 123.2, C - 124.3, C - 
5 106.4, CH 6.69, s 107.0, CH 6.63, s 
6 155.2, C - 151.8, C - 
7 73.2, CH 5.28, s 74.6, CH 6.21, s 
8 74.5, C - 73.9, C - 
9 40.5, CH2 
1.51, dd (11.0, 15.2) 
1.86, dd (5.0, 15.2) 
40.8, CH2 
1.45, dd (12.2, 14.9) 
1.86, dd (5.4, 14.9) 
10 74.5, CH 4.85, dd (5.0, 11.0) 74.3, CH 4.81, dd (5.8, 10.7) 
11 63.0, CH 3.70, s 62.9, CH 3.72, s 
12 61.0, C - 61.0, C - 
13 22.6, CH2 
a: 1.39, m 
b: 2.49, dd (11.2, 14.7) 
22.5 CH2 
a: 1.36, m 
b: 2.47, dd (11.5, 14.7) 
14 29.2, CH2 
a: 1.26, m 
b: 1.88, m 
28.8 CH2 
a: 1.19, m 
b: 1.83, m 
15 144.9, C - 144.7, C - 
16 114.1, CH2 
a: 4.97, dd (1.6, 1.6) 
b: 5.10, s 
114.2, CH2 
a: 4.97, dd, (1.6, 1.6) 
b: 5.10, s 
17 18.8, CH3 1.77, s 18.8 CH3 1.76, s 
18 184.7, CH 9.89, s 184.6, CH 9.87, s 
19 22.5, CH3 1.34, s 23.4, CH3 1.39, s 
20 172.5, C - 171.4, C - 
7-CH3CO   170.1, C - 
7-CH3CO   21.0, CH3 2.12, s 
 
The 1H–1H-COSY experiment confirmed two spin systems: H2-2–H2-13 (fragment I) and H2-9–
H-10 (fragment II) (Figure 2). The HMBC correlations H2-16/C-17, C-1 and H3-17/C-16, C-15, C-1 
locate an isopropenyl group at C-1 of fragment I, while the correlations H3-19/C-7, C-8 and C-9 
permits a lengthening of fragment II by connecting a vicinal dihydroxyl moiety to C-9. The north end 
of both fragments II and I are connected together by insertion of a furane ring, which is in agreement 
with the HMBC correlations H-5/C-3, C-4, C-6 and H2-2 with C-3. The southern ends of fragments I 
and II between C-13 and C-10 are joined to an epoxy lactone, as deduced from the HMBC correlations 
H-10/C-11, C-20; H2-13/C-20, C-11, C-12; and H2-14 with C-12. Therefore, the structure of compound 
1 was established, showing nine degrees of unsaturation as shown in figure 2. 
 
Figure 2. 1H1H-COSY (—), HMBC () correlations of 1. 
7-Acetate-leptogorgodiol A (2) was obtained as an oil. Its EIMS spectrum showed a molecular 
ion at m/z [M]+ 418 that corresponds to the molecular formula C22H26O8 (HREIMS) (m/z 418.1619 [M]+; 
calcd. for C22H26O8 418.1628). The 13C NMR spectrum and correlations observed in the HSQC 
spectrum indicated eight quaternary carbons, six methines, five methylenes and three methyls (Table 
1). 
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1H and 13C NMR data resemble those of compound 1. The main differences lie in the presence of 
an acetoxy group (H 2.12 (3H, s,), C 21.0 and C 170.1) and the downfield chemical shift of H-7 (H-7 
6.21 (1H, s)). These shift values suggested that compound 2 is the C-7 acetyl derivative of 1. Thus, the 
structure of 2 with ten degrees of unsaturation was established as shown in Figure 1 by COSY, HSQC 
and HMBC experiments. 
Leptogorgodiol B (3) was obtained as an oil. The EIMS spectrum showed a peak at m/z 360 [M]+, 
corresponding to the molecular formula C20H24O6 (HREIMS) (m/z 360.1561 [M]+, calcd. for C20H24O6 
360.1573). These data agree with the 13C NMR spectrum and the HSQC correlations which confirmed 
seven quaternary carbons, six methines, five methylenes and two methyls. The degree of 
unsaturation given by the 13C NMR data (Table 2) indicated that 3 must be a tricyclic compound. 
Comparison of the 1H and 13C NMR data for compounds 1 and 3 indicates that, in compound 3, 
there is an α,β-unsaturated-γ-lactone ring (H-11 5.81 (1H, s), C-11 148.7, C-12 133.6, C-20 173.5 and C-10 
78.8) instead of the α,β-epoxy-γ-lactone ring of compound 1. This is in agreement with the molecular 
formulas of compounds 1 and 3 that diverge by 16 amu of oxygen. Therefore, the structure of 3, 
containing nine degrees of unsaturation, was determined as shown in Figure 1 by COSY, HSQC and 
HMBC experiments. 
7-Acetate-leptogorgodiol B (4), obtained as an oil, showed a peak at m/z 402 [M]+ in the EIMS 
spectrum, which corresponds to the formula C22H26O7 (HREIMS) (m/z 402.1688 [M]+; calcd. for 
C22H26O7, 402.1679). The HSQC correlations and the signals observed in the 13C NMR spectrum 
indicate eight quaternary carbons, six methines, five methylenes and three methyls. 
1H and 13C NMR data (Table 2) resemble those of 3. The principal differences lie in the presence 
of an acetoxy group (H 2.16 (3H, s,), C 21.1 and C 169.5) and the downfield chemical shift of H-7 (H-
7 5.59 (1H, s)). Together with the HMBC correlations of H-7 with the carbonyl carbon in the acetoxy 
group, these shift values indicated that compound 4 is the C-7 acetyl derivative of 3. The planar 
structure of 4 (Figure 1), with ten degrees of unsaturation, was further corroborated as shown in 
Figure 1 by COSY, HSQC and HMBC experiments. 
Table 2. 1H and 13C NMR spectroscopic data (500 and 125 MHz, CDCl3) of compounds 3 and 4. 
No. 
3 4 
δC, Type δH (J in Hz) δC, Type δH (J in Hz) 
1 43.8, CH 2.22, m 43.8, CH 2.25, m 
2 31.8, CH2 
2.81, dd (2.2, 14.1) 
3.09, dd (11.6, 14.8) 
31.8, CH2 
2.89, dd (2.9, 14.8) 
3.06, dd (12.2, 14.8) 
3 162.9, C - 163.5, C - 
4 125.6, C - 125.3, C - 
5 106.4, CH 6.78, s 106.9, CH 6.70, s 
6 154.6, C - 151.5, C - 
7 75.6, CH 4.57, s 75.9, CH 5.59, s 
8 73.7, C - 72.8, C - 
9 43.0, CH 
b: 1.87, dd (11.6, 14.8) 
a: 2.57, dd (4.4, 14.8) 
43.2, CH2 
b: 1.95, dd (11.9, 15.1) 
a: 2.60, dd (4.0, 15.1) 
10 78.8, CH 4.96, m 78.5, CH 4.96, m 
11 148.7, CH 5.81, s 148.4, CH 5.85, s 
12 133.6, C - 133.8, C - 
13 21.7 CH2 
a: 2.10, m 
b: 2.31, m 
21.8, CH2 
a: 2.13, m 
b: 2.36, m 
14 28.5 CH2 
a: 1.49, m 
b: 1.82, m 
28.7, CH2 
a: 1.49, m 
b: 1.87, m 
15 145.7, C - 145.5, C - 
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16 113.2, CH2 
a: 4.82, s 
b: 4.87, dd (1.6, 1.6) 
113.3, CH2 
a: 4.84, s 
b: 4.89, dd (1.6, 1.6) 
17 19.2 CH3 1.77 s, br s 19.3, CH3 1.78, s 
18 184.6, CH 9.94, s 184.3, C 9.95, s 
19 19.7, CH3 1.40, s 21.0, CH3 1.48, s 
20 173.5, C - 171.9, C - 
7-CH3CO   169.5, C - 
7-CH3CO   21.1, CH3 2.16, s 
Z-isopukalide (5) was obtained as an oil. The EIMS spectrum showed a peak at m/z 372 [M]+, 
which agrees with the molecular formula C21H24O6 (HREIMS) (m/z 372.1575 [M]+, calcd. for C21H24O6, 
372.1573). These data are consistent with the 13C NMR spectrum and the correlations in the HSQC 
experiment indicating eight quaternary carbons, five methines, five methylenes and three methyls, 
one of them a methyl ester (Table 3). 
In addition to the 1H and 13C NMR data supporting an isopropenyl group, a furan ring and an 
α,β-epoxy-γ-lactone, other key signals were detected for a methyl ester group (H-21 3.82 (3H, s), C-21 
51.7 and C-18 164.3). Therefore, the 21 carbon atoms in the molecular formula suggest that the 
characteristic isoprenic methyl group C-18 found in regular furanocembranolides is oxidized to a 
methyl ester, placing compound 5 in class D [14]. Its planar structure with ten degrees of unsaturation 
was further corroborated to be as shown in Figure 1 by COSY, HSQC and HMBC experiments. 
Table 3. 1H and 13C NMR spectroscopic data (500 and 125 MHz, CDCl3) of compounds 5–6. 
No. 
5 6 * 
δC, Type δH (J in Hz) δC, Type δH (J in Hz) 
1 43.5, CH 2.56 m 41.0, CH 3.13, m 
2 32.8, CH2 
2.83, dd (2.6, 16.6) 




3 159.8, C - 152.0 / 152.2, C - 
4 115.9, C - 118.4 / 118.3, C - 
5 110.4, CH 6.45, s 108.5 / 108.8, CH 6.45 / 6.49, s 
6 150.4, C - 150.2 / 150.4, CH - 
7 117.4, CH 6.18, s 75.0 / 74.9, CH 6.17, s 
8 129.4, C - 73.9 / 74.0, C - 
9 36.6, CH2 
3.56, m 
2.58, m 
40.9 / 40.8, CH 
1.88 m 
1.55, m 
10 76.9, CH 4.60, dd (4.5, 12.8) 74.6 / 74.5, CH 4.79, m 
11 61.3, CH 3.81, s 62.9, CH 3.76, s 
12 60.8, C - 60.9 / 61.0, C - 




1.38, m  
2.46, m 
14 28.8, CH2 
a: 1.05, m 
b: 1.65, m 
28.5 / 28.6, CH2 
a: 1.23, m 
b: 1.81, m 
15 144.3, C - 145.1, C - 
16 113.8, CH2 
a: 4.89, s 
b: 4.99, dd (1.6, 1.6) 
113.9, CH2 
a: 4.95, s 
b: 5.06, s 
17 19.4, CH3 1.76, s 18.8, CH3 1.74, s 
18 164.3, C - 56.1, CH 5.38 / 5.39, s 
19 25.2, CH3 2.01, s 23.5 / 23.6, CH3 1.40, s 
20 172.2, C - 171.8, C - 
21 51.7, CH3 3.82 s  - 
7-CH3CO   170.4, C  
7-CH3CO   21.1, CH3 2.15, s 
18-CN   117.9 / 117.6, C  
* NMR data of the mixture of epimers at C-18. 
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Marine furanocembranolides can be divided into four classes according to the substituent at 
position C-4, those bearing CH3 (class A), CHO (class B), COOH (class C) or COOCH3 (class D). Our 
previous studies of octocorals from the coasts of Panama allowed us to isolate furanocembranolides 
in classes A, B and D [14,15]. We also showed that furanocembranoids belonging to classes A, B and 
D improve pancreatic β-cell proliferation [23–25]. In order to obtain new furanocembranolides with 
different substituents at the C-4, we treated leptolide with acetic acid and NaCN and later with MnO2 
(see the Experimental Section). After purification by flash chromatography, a mixture of two epimers 
at C-18 of the cyano derivative 6 was obtained, together with an acetoxy derivative for which the MS 
spectrometry and NMR data coincide with those of compound 2. 
The EIMS spectrum for the mixture of the epimers of 6 shows a peak at m/z 446 [M + H]+, which 
corresponds to the molecular formula C23H28NO8 (HREIMS) (m/z 446.1810 [M]+, calcd. for C23H28NO8, 
446.1815). Some of the 1H and 13C NMR signals of 6 appear duplicated due to the presence of the two 
epimers. 
The incorporation of the cyano and acetoxy groups in 6 is corroborated by the 13C NMR 
spectrum, and the HSQC correlations are indicative of nine quaternary carbons (one cyano group 
and two carbonyls), six methines, five methylenes and three methyls. The presence of the acetoxy 
group at C-7 was established by HMBC correlation of C-21 (CO) with H-7, and the cyano at C-18 was 
established by those correlations of H-18 with C-5 and C-23 (CN). 
2.2. Relative Configuration of Compounds 1–6 
The relative configurations of compounds 16 were established by combination of nuclear 
Overhauser effect spectroscopy (NOESY) experiments, molecular mechanics [26], analysis of key 
chemical shifts and comparison of their spectroscopic data with those of previously described 
furanocembranoids [27] (Figure 3). 
 
Figure 3. Minimized structures and selected NOE (nuclear Overhauser effect) effects ( ) of 1, 3 and 
5. 
In compounds 1, 2 and 6, the observed NOEs of H-5 with H3-19 as well as those of H-7 with H3-
19 suggested that the vicinal hydroxyl groups at C-7C-8 should be in a cis relationship in both 
compounds. In compounds 1, 2 and 6, the 1H NMR signal of H-11 is a singlet due to the roughly 90° 
dihedral angle formed between H-10 and H-11. Consequently, a small JH-10, H-11 confirms the relative 
configuration of C-10 and C-11, which is represented in the energetically favourable conformation 
shown in Figure 3. The disposition of the isoprenyl groups in both compounds was established from 
the observed NOEs between H-11 and H-14a and between H-16b and H-14b, situating them on the 
alpha side of the molecule in compounds 1, 2 and 6, as shown in the 3D model (Figures 3 and S13). 
In compounds 3 and 4, the observed NOEs of H3-19 with H-5, H-10 and H-11 indicate that these 
protons and Me-19 must be on same side of the molecule, whereas the NOEs of H3-19 with H-9a and 
of H-7 with H-9b indicate that H-7 and Me-19 have a trans-relationship, like the vicinal diols on C-
7C-8. Therefore, the relative configuration at C-8 is opposite to that on compounds 1 and 2. 
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In compound 3, the observed NOEs between H-11 and H-14a; between H-14b and H-16b; and 
between H-11, H-1 and H-13a and the NOE between H-13b and H-16b in compound 4 all confirmed 
that the isopropenyl group is situated on the alpha side of the molecule in compounds 3 and 4. 
The configurations of C-7C-8 vicinal diols were corroborated by comparing the 1H and 13C 
NMR chemical shifts around the diol moiety C-7C-8 in compounds 1 and 3 with those of the related 
diol compounds [27]. The chemical shifts of C-19 and H-7 in compounds 1 and 3 present strong 
differences (C-19 = 2.8 ppm and H-7 = 0.69) that are in good agreement with the proposed 
configurations of the diols, a cis-relationship for compound 1 and trans-relationship for compound 3 
[27]. As in the diol metabolites, the C-7C-8 configuration of the acetylated compounds 2, 4 and 6 
was also corroborated by comparison of the 1H and 13C NMR chemical shifts of H-7, H-9, H3-19 C-7, 
C-9 and C-19 (Table 4). The chemical shifts of C-19 and H-7 of compound 4 present strong upfield 
differences (C-19  2.5 ppm and H-7  0.6) with respect to 2 and 6. 
Table 4. Selected 1H and 13C NMR data (CDCl3) of compounds 2 and 4 and epimers 6. 
 
  
No. 2 6 4 
δH-7 6.21, s 6.17, s 5.59, s 
δH-9 
1.45, dd  
1.86, dd 
1.55, m  
1.88 m 
1.95, dd  
2.60, dd 
δH-19 1.39, s 1.35, s 1.48 s 
δC-7 74.6 74.0 75.9 
δC-9 40.8 40.5 43.2 
δC-19 23.4 22.4 21.0 
 
In compound 5, the 1H NMR signal for H-11 appears as a singlet due to the roughly 90° dihedral 
angle formed between H-10 and H-11. This angle confirms the relative configuration of C-10 and C-
11, as can be observed in the energetically favourable conformation shown in Figure 3. The observed 
NOEs between H-11 and H-14a and between H-16b and H-14b indicate that the isopropenyl group 
is situated on the alpha side of the molecule in compound 5. Furthermore, the NOE between H3-19 
and H-7 established the Z configuration of the C-7C-8 double bond, which is in agreement with the 
chemical shift of C-8 (C 129.4 ppm) and C-19 (C-25.2 ppm) and confirms that 5 is the geometric isomer 
of isopukalide [14]. 
2.3. Absolute Configuration 
The absolute configuration of compound 1 was established by chemical derivatization with (R)-
and (S)-α-methoxyphenyl acetic acids (MPA). NMR analysis of  values obtained for the two MPA 
esters 1b and 1c revealed evidences to assign the absolute configuration at C-7 as S (Table 5). Thus, 
this information established the absolute configuration of 1 as 1R, 7S, 8S, 10S, 11S and 12S. 
Table 5. 1H NMR (R−S) values (CDCl3, ppm, recorded at 500 MHz) of the diastereomeric (S)-α-
methoxyphenyl acetic acids (MPA) esters 1b and 1c. 
No. R S R-S 
δH-18 9.84 9.77 +0.070 
δH-5 6.53 6.08 +0.45 
δH-19 1.10 1.30 −0.20 
δH-10 4.60 4.72 −0.12 
Compounds 14 were isolated from a single extract of Leptogorgia sp.; therefore, we assume they 
belong to the same enantiomeric series. Thus, the absolute configurations were assigned as 2, 1R, 7S, 
8S, 10S, 11S and 12S; 3, 1R, 7S, 8R and 10S; and 4, 1R, 7S, 8R and 10S. 
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Compound 5 was isolated from the same extract that contained pukalide and (Z)-
deoxypukalide, for which absolute configuration was established previously by NMR using Pirkle’s 
reagent [14]. Therefore, based on biogenetic considerations and assuming they belong to the same 
enantiomeric series, the absolute configuration of 5 is assigned as 1R, 10S, 11S and 12S. 
2.4. Furanocembranolides Modulate LPS-Induced Inflammatory Responses on Microglial Cells 
Microglial cells were treated with the carrier (dimethylsulfoxide (DMSO)), the 
furanocembranolide alone, or with LPS simultaneously with either the carrier or the 
furanocembranolide (Figure 4A). First, we assessed the effects of these treatments on microglial 
viability by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
colorimetric assay (Figure S14A). 
 
Figure 4. Expression of IL-1β mRNA in vitro after LPS (lipopolysaccharide) stimulation and/or 
furanocembranolide treatment. (A) Experimental design. (B–H) Representative experiments showing 
the total fold change of IL-1β mRNA expression in comparison with basal conditions (vehicle alone): 
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Each bar depicts the mean value between quintuplicate qPCR (quantitative real-time polymerase 
chain reaction) runs, and error bars represent standard deviation. (I,J) IL-1β mRNA fold regulation 
normalized to the LPS + DMSO (dimethylsulfoxide) response (considered 100%), separated into 
furanocembranolides that increase (I) or decrease (J) the response. Each bar represents the mean 
between three independent experiments, and error bars show standard error of the mean. Statistical 
differences were assessed by two-way ANOVA, followed by Holm–Sidak post hoc tests (* p < 0.05, ** 
p < 0.01 and *** p < 0.001) and by pairwise comparison of raw data by t-test (# p = 0.051). 
Among all the furanocembranolides tested in this study, only leptolide significantly increased 
microglial viability (around 28%). LPS treatments significantly decreased BV2 viability, as expected, 
with no differences among treatments using compounds or carrier alone. Then, we examined 
whether treatment with furanocembranolides could reduce LPS-stimulated IL-1β mRNA expression 
in BV2 cells. LPS stimulation produced a marked increase in IL-1β expression, as expected. In 
contrast, simultaneous treatment with compound 3 (Figure 4D), 4 (Figure 4E) and leptolide (Figure 
4H) caused a marked decrease in IL-1β mRNA synthesis, while compound 6 (Figure 4G) showed a 
tendency (p = 0.051) to diminish inflammation. Compounds 1 (Figure 4B) and 5 (Figure 4F) had no 
significant effects, whereas compound 2 had a potent pro-inflammatory effect that exacerbated the 
LPS-induced inflammatory response (Figure 4C). Therefore, it seems that small changes in the 
functional groups of the furanocembranolide skeleton may have a dramatic effect on the pro- or anti-
inflammatory activity. Curiously, three of the compounds induced slight but statistically significant 
changes in IL-1β mRNA fold regulation in control conditions: compound 2 increased and compound 
6 and leptolide decreased IL-1β expression (Figure S14B). 
2.5. Leptolide Treatment in Vivo Ameliorates Microgliosis in a Mouse Model of Obesity and Insulin 
Resistance Triggered by HFD (High Fat Diet) 
Ionized calcium-binding adapter molecule 1 (Iba1) is a cytoplasmatic protein specifically 
expressed by microglia, and it is upregulated during microglial activation in various brain diseases, 
being therefore a marker of microgliosis [28]. Here we found that, in comparison with standard diet 
(SD), high fat diet (HFD) yielded an increase in Iba1 expression and leptolide treatment significantly 
reduced Iba1 in both dentate gyrus and cortex (Figure 5A). Moreover, from a qualitative point of 
view, it was observed that in SD-fed mice microglial cells are smaller and have a branched 
appearance. This morphology was similar to that attributed to the “resting or surveillant state” of 
microglia in comparison with those of control HFD-fed mice. These cells are larger and show a more 
ameboid form associated with an activated, more pro-inflammatory state [6]. Interestingly, in HFD-
mice treated with leptolide, microglial cells tend to shift morphologically towards a “resting state” 
(Figure 5A), indicating a reversion to healthier conditions. 
For statistical analyses, we performed three-way ANOVA considering diet, treatment and brain 
region as factors. All factors proved to be statistically significant, but neither drug nor diet showed 
dependence on region. There was a significant interaction between diet and drug (p = 0.005). Within 
the SD group, leptolide treatment significantly reduced Iba1 staining below basal levels (SD vehicle). 
Interestingly, leptolide treatment of HFD-fed mice resulted in a significant decrease in microgliosis, 
showing very similar behaviour in both brain regions analysed (Figure 5B). 
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Figure 5. Leptolide treatment ameliorates microgliosis triggered by HFD (high-fat diet): (A) 
Representative immunofluorescence images from paraffin sections of mouse brains stained with Iba1. 
Calibration bars: 50μm. (B) Immunohistochemical quantification of Iba1 protein expression, 
measured as percentage of Iba1-positive area per section, normalized to SD-Veh and considered 100% 
(n = 11–13 mice per group): Each dot represents the mean value of Iba1 (ionized calcium-binding 
adapter molecule 1)-positive area (between dentate gyrus and cortex) for an individual mouse. 
Statistical differences were assessed by three-way ANOVA followed by Holm–Sidak post hoc tests. * 
p < 0.05, ** p < 0.01 and *** p < 0.001. Only biologically relevant differences are shown. Abbreviations: 
SD = Standard Diet; HFD = High-Fat Diet; Veh = Vehicle; Lep = Leptolide. 
2.6. Leptolide Treatment in Vivo Also Reduces Astrogliosis 
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein expressed by astrocytes 
and is also considered a good marker of astrogliosis [29]. HFD resulted in an increase in GFAP 
expression, and this phenotype was partially reverted by treatment with leptolide in both regions 
studied, with a significant decrease in astrogliosis. Within SD-fed mice, leptolide had no significant 
effects (Figure 6A). For statistical analyses, we performed three-way ANOVA, as stated before. Diet, 
drug and region proved to be statistically significant factors. There was a tendency towards 
interaction between diet and drug (p = 0.08). Leptolide treatment of HFD-fed mice resulted in a 
significant decrease in astrogliosis (Figure 6B). 
 
Figure 6. Leptolide treatment ameliorates astrogliosis triggered by HFD: (A) Representative 
immunofluorescence images from paraffin sections of mouse brains stained with GFAP (glial 
fibrillary acidic protein). Calibration bars: 50μm. (B) Immunohistochemical quantification of GFAP 
expression measured as intensity of fluorescence per area, normalized to SD vehicle, considered as 
100% (n = 11–13 mice per group). Each dot represents the mean value of GFAP intensity per area 
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(between dentate gyrus and corpus callosum) for an individual mouse. Statistical differences were 
assessed by three-way ANOVA followed by Holm–Sidak post hoc tests. * p < 0.05, ** p < 0.01 and *** 
p < 0.001. Only biologically relevant differences are shown. Abbreviations: SD = Standard Diet; HFD 
= High Fat Diet; Veh = Vehicle; Lep = Leptolide. 
3. Discussion 
Many cembranolides have been described to possess anti-inflammatory properties in vitro. For 
example, durumolides F–K significantly reduced the levels of iNOS protein in an LPS-challenged 
Raw264.7 macrophagic cell line [30], lobophyolides decreased IL-12 release and attenuated nitric 
oxide (NO) production in LPS-stimulated dendritic cells [31], and cembrane diterpenoids showed 
potent anti-inflammatory activity by inhibiting NO production in Raw264.7 cells [32]. However, there 
are few studies addressing the immune-regulatory properties of cembranolides in glial cells. 
In our initial in vitro screening, we evaluated the anti-inflammatory potential of a group of 
furanocembranolides in LPS-stimulated microglial BV2 cells. Since we were interested in the direct 
effects of furanocembranolides on microglial early response to a pro-inflammatory challenge, the 
study focused on transcriptional events. We monitored IL-1β since this cytokine is an “alarmin” or 
sentinel that detects cellular damage and acts as an amplifier of immune reactions. Thus, IL-1β mRNA 
constitutes a marker of the inflammasome activation, which controls mature IL-1β production by 
caspase-1 cleavage. In fact, the rate-limiting step in the processing and secretion of bioactive IL-1β 
protein takes place with activation of the inflammasome [33]. Interestingly, expression of IL-1β has 
been demonstrated to be regulated not only at the transcriptional level but also by the stabilization 
and modulation of the half-life of the generated IL-1β mRNA [34]. In this regard, pro-inflammatory 
cytokines such as IL-1β itself, IL-6 and TNF-α have been shown to elevate the half-life of IL-1β mRNA 
[35], while the anti-inflammatory cytokine IL-4 acts as a negative regulator of IL-1β mRNA stability 
[36]. It has been estimated that, following LPS stimulation, IL-1β mRNA levels rise rapidly, reach 
their peak at 4 h and then start to decline, but the protein IL-1β can auto-induce itself, maintaining 
mRNA levels up to 24 h [33]. Our results demonstrate that leptolide and compounds 3, 4 and 6 can 
diminish the inflammatory response of LPS-stimulated microglial cells, while compound 2 presented 
a potent pro-inflammatory effect on microglia. Considering the structures of compounds 1–7 and 
their biological effects on microglia, although they possess the same carbon skeleton, we infer that 
differences in their functional groups may be critical to reduce or increase LPS-stimulated IL-1β 
mRNA expression in microglial cells. On comparing leptolide with compound 1, it seems that 
substitution of the epoxide at C-7C-8 with a cis diol decreases the anti-inflammatory activity. 
However, the presence or position of that epoxide is not critical for the activity of class B (CHO) 
furanocembranolides, since compounds 3 and 4 also exert an anti-inflammatory effect. The observed 
differences in activity could be related to the configuration at C-8, which in compounds 3 and 4 is the 
opposite to compounds 1 and 2. Moreover, comparison of 3 with 4 and of 1 with 2 suggests that 
substitution with a hydroxyl or an acetate group at C-7 does not substantially affect the potency of 
these compounds, if the acetate group is in trans relationship with the hydroxyl at C-8. However, it 
has a potent effect if both substituents are in a cis relationship. Finally, it is worth noting that 
compounds 2 and 6 have the same structure, except for the cyano group at C-18, but, while 6 exerts 
an anti-inflammatory effect, 2 has the opposite activity. This shows the importance of the cyano group 
at C-18, which is capable of reverting the pro-inflammatory effect of compound 2. 
The in vitro results prompted us to analyse the potential anti-inflammatory effects of these 
products in vivo. Preclinical models of high-fat diet-induced obesity and insulin resistance display 
microgliosis and astrogliosis, generating a good model to study central inflammation. We chose 
leptolide, since we already knew that it has protective effects on systemic insulin resistance in vivo. 
Furthermore, in this study, leptolide showed a prominent anti-inflammatory activity, along with an 
increase in microglial viability in vitro. Both microgliosis and astrogliosis, exacerbated by HFD, were 
diminished by leptolide treatment. In the case of microglia, a morphological shift from a 
“resting/surveillant state” (SD-mice) to an “activated state” (HFD-vehicle mice) was observed while 
HFD-fed mice treated with leptolide showed a microglial morphology more similar to the resting 
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state, characteristic of a healthy brain. Moreover, the results regarding gliosis in the dentate gyrus for 
both glial cell types were also validated in the corpus callosum, the largest white matter structure in 
the brain, and in the cerebral cortex, which plays an essential role in memory and cognition. We 
observed the same effects in all regions analysed. 
Although gliosis amelioration may be, at least in part, attributed to the decrease in blood levels 
of inflammatory molecules associated with leptolide treatment [23], our in vitro results support a 
direct anti-inflammatory effect of leptolide and compounds 3, 4 and 6 on microglial cells. 
Interestingly, micheliolide, a sesquiterpene lactone that can suppress LPS-stimulated pro-
inflammatory cytokines production in Raw264.7 cells [37], has been demonstrated to cross the blood–
brain barrier and to preferentially accumulate in the brain [38]. This finding suggests that leptolide 
can cross the blood–brain barrier and have both systemic and direct effects on glial cells in vivo. 
Leptolide has been shown to act as an insulin sensitizer, enhancing insulin signalling in the liver 
and muscle of diet-induced obese mice [23]. It is well known that obesity triggers low-grade chronic 
inflammation, and this compound could partially revert this status, rendering a less inflammatory 
body environment and a switch towards a lower inflammatory state of the brain. In any case, our 
results obtained in mice show that leptolide is able to reduce in vivo the gliosis triggered by HFD, 
which makes leptolide a promising drug to simultaneously treat insulin resistance and 
neuroinflammation due to its pleiotropic effects on metabolism and gliosis. 
To our knowledge, this is the first study to assess the effects of leptolide on gliosis in vivo and 
of the new furanocembranolides in vitro. Our results on leptolide provide a hopeful therapeutic 
approach, viable for treating neuroinflammation concomitant with metabolic impairment. However, 
further research is necessary to address the mechanism by which furanocembranolides exert their 
therapeutic outcomes on glial cells. Indeed, a better understanding of the mechanisms underlying 
their anti-neuroinflammatory effects on neurodegenerative processes should lead to more effective 
treatments in the future. 
4. Experimental Section 
4.1. General Experimental Procedures 
A Perkin-Elmer model 343 Plus polarimeter (Na lamp at 20 °C) (Perkin-Elmer, Rodgau, 
Germany) was used for optical rotations measurements. A Perkin-Elmer 1650/FTIR spectrometer 
(Perkin-Elmer, Rodgau, Germany) was used to record IR spectra. A Bruker AMX 500 instrument 
(Bruker, Karlsruhe, Germany) operating at 500 MHz for 1H NMR and at 125 MHz for 13C NMR was 
used for NMR spectra measurements. The residual solvent signals of deutered chloroform (δC 77.0 
ppm and δH 7.25 ppm) were used as internal references. The standard Bruker software was used to 
obtain two-dimensional NMR spectra. A Waters VG-Micromass spectrometer model Zab 2F (Waters, 
Manchester, UK) was used to obtain the EIMS data. An Agilent 1200 Series Quaternary LC system 
apparatus was used for high performance liquid chromatography (HPLC) purifications. HPLC 
detection was carried out by an ultraviolet (UV) detector (DAD G1315D) (Agilent Technologies, 
Waldbronn, Germany). Two columns were used: an Ascentis® C18 semipreparative column (5 μm, 
25 cm × 21.2 mm) which used CH3CN-H2O mixtures or a Jaigel-sil column (10 μm, 25 cm × 20 mm) 
which used Hexane-EtOAc mixtures. Stationary phase used for size-exclusion chromatography was 
Sephadex LH-20, and a mixture of Hexane-MeOH-CH2Cl2 (3:1:1) was used as solvent system. The 
mixture H2SO4-H2O-AcOH (1:4:20) was used to visualize thin layer chromatography (TLC) plates. 
4.2. Collection, Extraction and Isolation 
Two collections of Leptogorgia specimens were studied in different years. Firstly, from Jicarita 
(Panama), we collected Leptogorgia spp., by Self-Contained Underwater Breathing Apparatus 
(SCUBA) diving at −15 m. A voucher specimen with code 200511 was deposited at Smithsonian 
Tropical Research Institute (Panama). A previous report describes the isolation and identification of 
leptolide together with another five furanocembranolides isolated from Leptogorgia spp. [14]. From a 
later study of the same crude extract, we isolated compound 5 (17.9 mg; tR 32 min) using normal 
Mar. Drugs 2020, 18, 378 15 of 22 
 
phase HPLC (Hexane-EtOAc (8:2)). Secondly, Leptogorgia sp. was similarly collected off Aleta 
(Panama) at −10 m, depositing another voucher specimen with code 200708 at the Smithsonian 
(Panama). Specimens (458.3 g) were extracted with acetone at room temperature and concentrated, 
yielding a dark gum (10.1 g) that was purified by C-18 reversed-phase flash chromatography to 
obtain fraction 4 (290.4 mg; 2:3 H2O/MeOH) that was enriched in cembranolides, as indicated its 1H 
NMR spectrum. This fraction was further chromatographed by Sephadex LH-20 to give four 
subfractions of interest: 4a (39.4 mg), 4b (27.0 mg), 4c (49.0 mg) and 4d (27.9 mg). Compound 4 (5.2 mg, 
tR 92 min) was obtained from fraction 4a after C-18 reversed-phase HPLC (H2O-CH3CN (7:3)  
CH3CN (100%)). Compound 3 (6.8 mg; tR 51 min) was separated from 4b after C-18 reversed-phase 
HPLC (H2O-CH3CN (7:3)). Subfraction 4c (49.0 mg) was chromatographed by C-18 reversed-phase 
HPLC (H2O-CH3CN (8:2)  CH3CN (100%)) to afford compound 2 (10.2 mg; tR 114 min). Finally, C-
18 reversed-phase HPLC (H2O-CH3CN (9:1)  CH3CN (100%)) of subfraction 4d afforded 1 (9.1 mg; 
tR 105 min). 
Leptogorgodiol A 1: colourless oil; [] 
   +4.9 (c 0.37, CH2Cl2); IR (film) max 3478, 2936, 1774, 1672 
cm−1; 1H (500 MHz, CDCl3) δ 1.34 (3H, s, H-19), 1.26 (1H, m, H-14a), 1.39 (1H, m, H-13a), 1.51 (1H, dd, 
J = 11.0, 15.2 Hz, H-9a), 1.77 (3H, s, H-17), 1.86 (1H, dd, J = 5.0, 15.2 Hz, H-9b), 1.88 (1H, m, H-14b), 
2.49 (1H, dd, J = 11.2, 14.7 Hz, H-13b), 3.00 (H, m, H-2a), 3.05 (H, m, H-2b), 3.24 (1H, m, H-1), 3.70 (1H, 
s, H-11), 4.85 (1H, dd, J = 5.0, 11.0 Hz, H-10), 4.97 (1H, dd, J = 1.6, 1.6 Hz, H-16b), 5.10 (1H, s, H-16b), 
5.28 (1H, s, H-7), 6.69 (1H, s, H-5), 9.89 (1H, s, H-18); 13C NMR (125 MHz CDCl3) δ 18.8 (CH3, C-17), 
22.5 (CH3, C-19), 22.6 (CH2, C-13), 29.2 (CH2, C-14), 31.9 (CH2, C-2), 40.1 (CH, C-1), 40.5 (CH2, C-9), 
61.0 (C, C-12), 63.0 (CH, C-11), 73.2 (CH, C-7), 74.5 (C, C-8), 74.5 (CH, C-10), 106.4 (CH, C-5), 114.1 
(CH2, C-16), 123.2 (C, C-4), 144.9 (C, C-15), 155.2 (C, C-6), 162.4 (C, C-3), 172.5 (C, C-20), 184.7 (CH, C-
18); EIMS m/z 376 [M]+, 358 [M-H2O]+; HREIMS m/z [M]+ 376.1514 (calcd. for C20H24O7 376.1522), 
358.1412 (calcd. for C20H22O6, 358.1416). 
7-Acetoxy-leptogorgodiol A 2: colourless oil; []D
20 −11.0 (c 0.03, CH2Cl2); IR (film) max 3473, 2941, 
1779, 1678 cm−1; 1H (500 MHz, CDCl3) δ 1.19 (1H, m, H-14a), 1.36 (1H, m, H-13a), 1.39 (3H, s, H-19), 
1.45 (1H, dd, J = 12.2, 14.9 Hz, H-9a), 1.76 (3H, s, H-17), 1.83 (1H, m, H-14b), 1.86 (1H, dd, J = 5.4, 14.9 
Hz, H-9b), 2.12 (3H, s, MeCO), 2.47 (1H, dd, J = 11.5, 14.7 Hz, H-13b), 3.27 (1H, dd, J = 11.2, 11.2 Hz, 
H-1), 2.96 (1H, dd, J = 2.9, 16.8 Hz, H-2a), 3.05 (1H, dd, J = 11.8, 16.8 Hz, H-2b), 3.72 (1H, s, H-11), 4.81 
(1H, dd, J = 5.8, 10.7 Hz, H-10), 4.97 (1H, dd, J = 1.6, 1.6 Hz, H-16a), 5.10 (1H, s, H-16b), 6.21 (1H, s, H-
7), 6.63 (1H, s, H-5), 9.87 (1H, s, H-18); 13C NMR (125 MHz, CDCl3) δ 18.8 (CH3, C-17), 21.0 (CH3, 
MeCO), 22.5 (CH2, C-13), 23.4 (CH3, C-19), 28.8 (CH2, C-14), 31.6 (CH2, C-2), 40.2 (CH, C-1), 40.8 (CH2, 
C-9), 61.0 (C, C-12), 62.9 (CH, C-11), 73.9 (C, C-8), 74.6 (CH, C-7), 74.3 (CH, C-10), 107.0 (CH, C-5), 
114.2 (CH2, C-16), 124.3 (C, C-4), 144.7 (C, C-15), 151.8 (C, C-6), 162.6 (C, C-3), 170.1 (c, CO), 171.4 (C, 
C-20), 184.6 (CH, C-18); EIMS m/z 418 [M]+, 359 [M-CH3COO]+; HREIMS m/z [M]+ 418.1619 (calcd. for 
C22H26O8, 418.1628), 359.1510 (calcd. for C20H23O6, 3359.1495). 
Leptogorgodiol B 3: colourless oil; []D
20 −4.5 (c 0.0.4, CH2Cl2); IR (film) max 3443, 2940, 1746, 1674 
cm−1; 1H (500 MHz, CDCl3) δ 1.40 (3H, s, H-19), 1.77 (3H, s, H-17), 1.49 (1H, m, H-14a), 1.82 (1H, m, 
H-14b), 1.87 (1H, dd, J = 11.6, 14.8 Hz, H-9a), 2.10 (1H, m, H-13a), 2.22 (1H, m, H-1), 2.31 (1H, m, H-
13b), 2.57 (1H, dd, J = 4.4, 14.8 Hz, H-9b), 2.81 (1H, dd, J = 2.2, 14.1, H-2a), 3.09 (1H, dd, J = 11.6, 18.4 
Hz, H-2b), 4.57 (1H, s, H-7), 4.82 (1H, s, H-16a), 4.87 (1H, dd, J = 1.6, 1.6 Hz, H-16b), 4.96 (1H, m, H-
10), 5.81 (1H, s, H-11), 6.78 (1H, s, H-5), 9.94 (1H, s, H-18); 13C NMR (125 MHz, CDCl3) δ 19.2 (CH3, C-
17), 19.7 (CH3, C-19), 21.7 (CH2, C-13), 28.5 (CH2, C-14), 31.8 (CH2, C-2), 43.0 (CH2, C-9), 43.8 (CH, C-
1), 73.7 (C, C-8), 75.6 (CH, C-7), 78.8 (CH, C-10), 106.4 (CH, C-5), 113.2 (CH2, C-16), 125.6 (C, C-4), 
133.6 (C, C-12), 145.7 (c, C-15), 148.7 (CH, C-11), 154.6 (C, C-6), 162.9 (C, C-3), 173.5 (C, C-20), 184.6 
(CH, C-18); EIMS m/z 360 [M]+, 342 [M-H2O]+; HREIMS m/z [M]+ 360.1561 (calcd. for C20H24O6, 
360.1573), [M-CH3]+ 342.1470 (calcd. for C20H22O5, 342.1467). 
7-Acetoxy-leptogorgodiol B 4: colourless oil; []D
20 −18.2 (c 0.45, CH2Cl2); IR (film) max 3441, 2915, 
1749, 1677 cm−1; 1H (500 MHz, CDCl3) δ 1.48 (3H, s, H-19), 1.49 (1H, m, H-14a), 1.78 (3H, s, H-17), 1.87 
(1H, m, H-14b), 1.95 (1H, dd, J = 11.9, 15.1 Hz, H-9a), 2.13 (1H, m, H-13a), 2.16 (3H, s, MeCO), 2.25 
(1H, m, H-1), 2.36 (1H, m, H-13b), 2.60 (1H, dd, J = 4.0, 15.1 Hz, H-9b), 2.89 (1H, dd, J = 2.9, 14.8 Hz, 
Mar. Drugs 2020, 18, 378 16 of 22 
 
H-2a), 3.06 (1H, dd, J = 12.2, 14.8 Hz, H-2b), 4.84 (1H, s, H-16a), 4.89 (1H, dd, J = 1.6, 1.6 Hz, H-16b), 
4.96 (1H, m, H-10), 5.59 (1H, s, H-7), 5.85 (1H, s, H-11),6.70 (1H, s, H-5), 9.95 (1H, s, H-18); 13C NMR 
(125 MHz, CDCl3) δ 19.3 (CH3, C-17), 21.0 (CH3, C-19), 21.1 (CH3, MeCO), 21.8 (CH2, C-13), 28.7 (CH2, 
C-14), 31.8 (CH2, C-2), 43.2 (CH2, C-9), 43.8 (CH, C-1), 72.8 (C, C-8), 75.9 (CH, C-7), 78.5 (CH, C-10), 
106.9 (CH, C-5), 113.3 (CH2, C-16), 125.3 (C, C-4), 133.8 (C, C-12), 145.5 (C, C-15), 148.4 (CH, C-11), 
151.5 (C, C-6), 163.5 (C, C-3), 169.5 (C, CO), 171.9 (C, C-20), 184.3 (CH, C-18); EIMS m/z 402 [M]+, 342 
[M-CH3COOH]+; HREIMS m/z [M]+ 402.1688 (calcd. for C22H26O7, 402.1679), 342.1468 (calcd. for 
C20H22O5, 342.1467). 
Z-Isopukalide 5: colourless oil; []D
20 +66.0 (c 0.05, CH2Cl2); IR (film) max 3441, 2915, 1749, 1677 
cm−1; 1H (500 MHz, CDCl3) δ 1.05 (1H, m, H-14a), 1.65 (1H, m, H-14b), 1.59 (1H, m, H-13a), 1.76 (3H, 
s, H-17), 2.01 (3H, s, H-19), 2.56 (1H, m, H-1), 2.58 (1H, m, H-9a), 2.62 (1H, m, H-13b), 2.83 (1H, dd, J 
= 2.6, 16.6, H-2a), 3.39 (1H, dd, J = 12.5, 16.6, H-2b), 3.56 (1H, m, H-9b), 3.81 (1H, s, H-11), 3.82 (3H, s, 
MeO), 4.60 (1H, dd, J = 4.5, 12.8 Hz, H-10), 4.89 (1H, s, H-16a), 4.99 (1H, dd, J = 1.3, 1.3 Hz, H-16b), 
6.18 (1H, s, H-7), 6.45 (1H, s, H-5); 13C NMR (125 MHz, CDCl3) δ 19.4 (CH3, C-17), 21.7 (CH2, C-13), 
25.2 (CH3, C-19), 28.8 (CH2, C-14), 32.8 (CH2, C-2), 36.6 (CH2, C-9), 43.5 (CH, C-1), 51.7 (CH3, OMe), 
60.8 (C, C-12), 61.3 (CH, C-11), 76.9 (CH, C-10), 110.4 (CH, C-5), 113.8 (CH2, C-16), 115.9 (C, C-4), 117.4 
(CH, C-7), 129.4 (C, C-8), 144.3 (C, C-15), 150.4 (C, C-6), 159.8 (C, C-3), 164.3 (CH, C-18), 172.2 (C, C-
20); EIMS m/z 372 [M]+, 340 [M-CH3OH]+; HREIMS m/z [M]+ 372.1575 (calcd. for C21H24O6, 372.1573), 
340.1310 (calcd. for C20H20O5, 340.1311). 
Preparation of compound 6: leptolide (14.6 mg, 0.045 mmol) was dissolved in 0.5 mL of 
anhydrous methanol, and while stirring, acetic acid (6.7 mg, 6.5 mL, 0.11 mmol) and NaCN (11 mg, 
0.22 mmol) were added. MnO2 (78 mg, 0.90 mmol) was added after 1 h of stirring at room temperature. 
After 21 h, the reaction was filtered through Celite, washed with EtOAc and H2O, dried and 
concentrated. Flash chromatography on silica of the residue obtained allowed to obtain compound 6 
(3.6 mg) and compound 2 (2.8 mg). 
Compound 6: colourless oil; 1H (500 MHz, CDCl3) δ 1.23 (1H, m, H-14a), 1.38 (1H, m, H-13), 1.40 
(3H, s, H-19), 1.55 (1H, m, H-9), 1.74 (3H, s, H-17), 1.81 (1H, m, H-14b), 1.88 (1H, m, H-9), 2.46 (1H, m, 
H-13), 2.65 (1H, H-2b), 2.73 (1H, m, H-2a), 3.13 (1H, m, H-1), 3.76 (1H, s, H-11), 4.79 (1H, m H-10), 
4.95 (1H, s, H-16a), 5.06 (1H, s, H-16b), 5.38/5.39 (1H, s, H-18), 6.17 (1H, s, H-7), 6.45/6.49 (1H, s, H-5); 
13C NMR (125 MHz, CDCl3) δ 18.8 (CH3, C-17), 21.1 (CH3, MeCO), 22.5 (CH2, C-13), 23.6/23.5 (CH3, C-
19), 28.6/28.5 (CH2, C-14), 30.7 (CH2, C-2), 40.8/40.9 (CH2, C-9), 41.0 (CH, C-1), 56.1 (CH, C-18), 
61.0/60.9 (C, C-12), 62.9 (CH, C-11), 73.9/74.0 (C, C-8), 74.6/74.5 (CH, C-10), 75.0/74.9 (CH, C-7), 
108.8/108.5 (CH, C-5), 113.9 (CH2, C-16), 118.4/118.3 (C, C-4), 117.9/117.6 (C, CN), 145.1 (C, C-15), 
150.4/150.2 (C, C-6), 152.2/152.0 (C, C-3), 170.4 (C, CH3CO), 171.8 (C, C-20); EIMS m/z 446 [M + 1]+, 418 
[M-HCN]+; ESMS m/z [M + H]+ 446.1810 (calcd. for C23H28NO8, 446.1815), 418.1637 (calcd. for C22H26O8, 
418.1628). 
(R)-and (S)-α-methoxyphenyl acetic acids (MPA) ester derivatives 1b and 1c. Compound 1 (3.0 
mg, 8.0 × 10−3 mmol) was dissolved in 1.0 mL of CH2Cl2 and treated with N,N-
dicyclohexycarbodiimide (7.1 mg, 3.4 × 10−2 mmol), 4-dimethylaminopyridine (3.5 mg, 2.87 × 10−2 
mmol) and (R)-α-methoxy-α-phenylacetic acid (6.6 mg, 4.0 × 10-2 mmol). The reaction was stirred at 
room temperature for 1 h, and then, after silica gel chromatography (Hexane-EtOAc 1:1) of the 
reaction mixture, the (R)-MPA ester derivative 1b (1.6 mg, 3.0 × 10-3 mmol, 37.5% yield) was obtained. 
The (S)-MPA ester derivative 1c (1.9 mg, 3.6 × 10-3 mmol, 45% yield) was obtained following the same 
experimental process. 
4.3. Reagents Preparation 
The compounds were dissolved in DMSO (Sigma) to make concentrated stock solutions (ranging 
from 25 to 100 mM, depending on the amount of product available) within their solubility range. The 
final concentration of furanocembranolides 1–7 added to the cells was 0.1 μM in culture media. The 
final concentration of leptolide injected into the mice was 0.1 mg/kg in saline. Identical dilutions from 
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the carrier, DMSO, were prepared as controls to rule out the possibility that the effects observed in 
experimental conditions could be due to the presence of DMSO. The maximal final concentration of 
DMSO added to the cells was 0.0004% v/v. The final concentration of DMSO injected was 0.001% with 
respect to the mouse plasma volume. These concentrations are below the cytotoxicity threshold. 
LPS (Lipopolysaccharide from E.coli 0111:B4, L2630, Sigma) was dissolved in PBS (phosphate 
buffered saline) to make a stock solution (LPS 1 mg/mL). It was then added to the cell cultures at a 
final concentration of 1 μg/mL. 
4.4. Cell Culture and Treatments 
The murine microglial BV2 cell line was obtained from ATCC (American Type Culture 
Collection, Virginia, USA). Cells were grown at 37 °C in a humidity-saturated atmosphere containing 
5% CO2. Culture medium (RPMI Medium 1640 1X (Roswell Park Memorial Institute; Gibco), 
supplemented with heat-inactivated 5% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL 
penicillin and 100 U/mL streptomycin) was replaced twice a week, and cells were sub-cultured at 
50% confluence. 
Experimental protocols were performed as follows: BV2 cells were seeded to a final density of 
6500 cells/cm2 in a 10 cm Petri dish (Nunc, Thermo Scientific). After 8 h, culture medium was 
removed, cells were rinsed with PBS (Lonza) and culture medium without FBS was added. Cells were 
serum starved overnight and then treated for 24 h with different stimuli in serum-free medium: a) 
DMSO, b) furanocembranolide (0.1 μM), c) LPS (1 μg/mL) plus DMSO and d) LPS (1 μg/mL) plus 
furanocembranolide (0.1 μM). 
4.5. MTT Viability Assay 
To measure cell viability, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) colorimetric assay was performed as previously described [39]. Briefly, cells were seeded 
in a 96-well standard plate (NUNC, Thermo Scientific), with a cell density of 450 cells/mm2, in 
quadruplicates. After receiving their respective treatments, cells were washed with PBS and treated 
with MTT (62.5 μg/mL) for 3 h in phenol-red-free DMEM (Dulbecco’s Modified Eagle Medium, 
Lonza) without FBS. After MTT exposure, cells were incubated in an isopropanol-10% Triton X-100 
solution to solubilize formazan. Formazan production was measured by spectrophotometry using 
the SOFTmax Pro microplate reader (Molecular Devices, San Jose, CA, USA). Absorbance was 
measured at λ = 570 nm after subtracting the λ = 690 nm background. Measurements were normalized 
with respect to control conditions. 
4.6. RNA Isolation from Cell Cultures 
At the end of the treatments, cells were rinsed with PBS twice and then collected and lysed with 
QIAzol Lysis Reagent (Qiagen, Venlo, The Netherlands). Cellular mRNA was extracted following the 
manufacturer’s protocol. Briefly, QIAzol solution containing lysed cells was mixed with 1:5 volume 
of chloroform (Merck, Darmstadt, Germany) and mixed vigorously. Then, samples were centrifuged 
for 15 min at 16,400g and two phases were formed. RNA was collected from the aqueous phase and 
precipitated with isopropanol (Merck). RNA pellets were washed with ethanol 70% (Merck), dried 
and resuspended in diethyl pyrocarbonate (DEPC)-treated water. 
4.7. Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) 
RNA concentration was measured with a Nanodrop spectrophotometer (NanoDropTM N-D1000, 
Thermo Fisher Scientific, Waltham, MA, USA). Samples were treated with DNase I (0.1 U/μl, 
Fermentas) to prepare DNA-free RNA. Then, 500 ng of total RNA was reverse-transcribed with 
Prime-Script (Takara Bio Inc., Otsu, Japan) following the manufacturer’s instructions. The resulting 
cDNA was used as a template for quantitative real-time polymerase chain reaction (RT-qPCR) using 
SybrGreen (SYBR Premix Ex Taq kit, Takara Bio Inc., Otsu, Japan). The primers used for RT-qPCR 
are shown in Table 6. 
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Table 6. Primers used for quantitative real-time polymerase chain reaction (RT-qPCR). 
Gene Name (ID) Primer Name Sequence (5′-3′) 
IL-1β (NM_008361.4) 
Mouse IL1β-Forward TGTAATGAAAGACGGCACACCCAC 
Mouse IL1β-Reverse GGCTTGTGCTCTGCTTGTGAGG 
Rpl18 (NM_009077.2) 
Mouse Rpl18-Forward TTCCGTCTTTCCGGACCT 
Mouse Rpl18-Reverse TCGGCTCATGAACAACCTCT 
To validate the specificity of the amplification products, melting curves were analysed and qPCR 
products were loaded into a 2% agarose gel and run at 100 V for 30 min. IL-1β mRNA fold regulation 
was calculated for each individual experiment by using the relative quantification strategy of the 
2−∆∆CT method [40], using normalization to Rpl18 (housekeeping gene) for each condition. To allow 
comparisons between different experiments, fold regulation values were normalized by assigning 
the value 100% to the LPS + DMSO response in order to make it easier to visualize the outcome of 
each individual compound on IL-1β mRNA modulation. Statistically significant differences of gene 
transcriptional changes were evaluated by two-way ANOVA, followed by Holm–Sidak post hoc 
tests. The statistical level of significance was set at p < 0.05. 
Three different mRNA preparations from three independent cell cultures were assessed for each 
condition. 
4.8. Animal Procedures 
C57/Bl6J male mice were purchased from Charles River Laboratory (Écully, Lyon, France). Male 
mice were chosen for metabolic phenotyping to avoid the potential variability related to the oestrous 
cycle. Experimental procedures were approved by the Animal Care and Use Committee of the 
University of Valladolid (UVa), Valladolid, Spain, in accordance with the European and Spanish 
Guidelines for the Care and Use of Mammals in Research. Mice were maintained in positive pressure-
ventilated racks at 25 °C with 12 h light/dark cycle, fed ad libitum with standard rodent chow diet 
and allowed free access to filtered and UV-irradiated water. 
At 6 weeks of age, mice were randomly divided into two groups: one of them was fed with 
standard diet (SD) (33% protein; 58% carbohydrate; 9% fat) (#V1535, Ssniff, Soest, Germany), while 
the other was fed with a 60% kcal high-fat diet (HFD) (20% protein; 20% carbohydrate; 60% fat) 
(#D12492, Research Diets, New Brunswick, NJ, USA) for 6 weeks. After this time, each experimental 
group was randomly divided into two subgroups, which were treated with one-daily intraperitoneal 
injections of leptolide (0.1 mg/kg of body weight) or vehicle (DMSO) for another 4 weeks. All mice 
were maintained on their corresponding diet during the 4-week treatment, and finally, they were 
euthanized at 16 weeks of age. After 4 weeks of treatment, leptolide-treated mice showed improved 
glucose tolerance by IPGTT (intraperitoneal glucose tolerance test) (area under the curve (AUC): 
leptolide 36.6 ± 0.8 versus vehicle 39.6 ± 0.8; p < 0.05) and improved insulin sensitivity measured by 
the HOMA index (fasting insulin (μUI/mL) × fasting glucose (mM)/22,5) (leptolide 0.7 ± 0.1 versus 
vehicle 1.2 ± 0.2; p < 0.05). 
4.9. Immunohistochemistry 
Mouse brains were quickly removed after sacrifice and divided into two pieces following a 
midsagittal section. Brains were fixed by immersion in 4% paraformaldehyde overnight at 4 °C. The 
tissues were washed in PBS and embedded in paraffin following standard procedures. Coronal slices 
(5 μm) were cut with a rotary microtome (Microm, Wayzata, MN, USA), serially mounted on 
Polysine™ slides (Menzel-Gläser) and dried. Sample processing was performed by CNB Histology 
Facility (UAM-CSIC, Madrid, Spain). 
Tissue slices were dewaxed in xylene and rehydrated through an ethanol series into phosphate 
buffered saline (PBS). The slices were then blocked and permeabilized with Triton X-100 (0.25% in 
PBS) and 1% normal goat serum. The following primary antibodies were used: mouse anti-GFAP (1 
μg/mL, Santa Cruz Biotechnology, Dallas, TX, USA) and rabbit anti-Iba1 (0.5 μg/mL, Wako, 
Germany). As secondary antibodies, Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa 
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Fluor 594-conjugated goat anti-rabbit IgG (1.5 μg/mL, Jackson Immunoresearch, West Grove, PA, 
USA) were used. 
4.10. Image Acquisition 
Immunostained sections were visualized with an Eclipse 90i fluorescence microscope (Nikon) 
equipped with a DS-Ri1 (Nikon, Minato, Tokyo, Japan) digital camera. Images were acquired under 
the same conditions of illumination, diaphragm and condenser adjustments, exposure time, 
background correction and colour levels. 
Images were acquired from dentate gyrus for both astrocytes and microglia since, as part of the 
hippocampus, it is considered to play a crucial role in associative memory. To validate the results 
obtained, an additional region for each cell type was also analysed: corpus callosum for astrocytes 
and cortex for microglia. For each region, two different series 20 μm apart were examined. 
4.11. Image Quantification 
Astroglial and microglial fluorescence levels were quantified with ImageJ software. For 
astrocytosis quantification, GFAP immunoreactive intensity has a well-known correlation with 
astrocyte reactivity [41]; therefore, astrogliosis was measured as a GFAP fluorescence intensity per 
unit area. For microgliosis measurements, Iba1-positive areas were calculated in each photograph, 
since microgliosis is correlated with morphological changes that imply an increase in cell volume 
[42]. The microglial reactivity was measured in terms of percentage of area Iba1-positive per section. 
4.12. Statistical Analysis 
Statistical analyses were performed with SigmaPlot v.11.0 (Systat, San Jose, CA, USA) software. 
A p value < 0.05 was used as a threshold for significant changes. The tests used for each experiment 
are stated in figure legends. 
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